Literature DB >> 20551825

A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors.

Gabriel Sica1, Akihiko Yoshizawa, Camelia S Sima, Christopher G Azzoli, Robert J Downey, Valerie W Rusch, William D Travis, Andre L Moreira.   

Abstract

Currently no objective grading system for pulmonary adenocarcinomas exists. To determine whether specific histologic patterns or combinations thereof could be linked to an objective grading system, the histologic patterns in metastatic tumor deposits was compared with the patterns seen in the corresponding 73 primary tumor to determine whether a specific pattern had higher propensity to metastasize. The concordance of the predominant histologic pattern in the primary tumor and the metastases was of 100% for micropapillary, 86% for solid, 42% for acinar, and 23% for papillary types of adenocarcinoma. Informed by these results, a 3-tier grading system based on the histologic subtypes was established. Grade I, a pattern with low metastatic potential (BAC); Grade II, patterns with intermediate metastatic potential (acinar and papillary); and Grade III, patterns with high metastatic potential (solid and micropapillary). These grades were combined into a number of different scoring systems, whose ability to predict recurrence or death from disease was tested in 366 stage 1 adenocarcinomas. A score based on the 2 most predominant grades was able to stratify patients into low-to-high risk for recurrence or death of disease (P=0.001). The 5-years disease-free survival for patients in the highest score group was of 0.73, compared with 0.84 and 0.92 in the intermediate and lowest score groups. Concordance probability estimate was 0.65 (95% confidence interval 0.57-0.73). Therefore, this scoring system provides valuable information in discriminating patients with different risk of disease-recurrence in a highly homogeneous population of patients with stage I cancer.

Entities:  

Mesh:

Year:  2010        PMID: 20551825     DOI: 10.1097/PAS.0b013e3181e4ee32

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  113 in total

1.  FDG-PET SUVmax combined with IASLC/ATS/ERS histologic classification improves the prognostic stratification of patients with stage I lung adenocarcinoma.

Authors:  Kyuichi Kadota; Christos Colovos; Kei Suzuki; Nabil P Rizk; Mark P S Dunphy; Emily C Zabor; Camelia S Sima; Akihiko Yoshizawa; William D Travis; Valerie W Rusch; Prasad S Adusumilli
Journal:  Ann Surg Oncol       Date:  2012-05-30       Impact factor: 5.344

2.  Training increases concordance in classifying pulmonary adenocarcinomas according to the novel IASLC/ATS/ERS classification.

Authors:  Arne Warth; Judith Cortis; Ludger Fink; Annette Fisseler-Eckhoff; Helene Geddert; Thomas Hager; Klaus Junker; Gian Kayser; Julia Kitz; Florian Länger; Alicia Morresi-Hauf; German Ott; Iver Petersen; Albrecht Stenzinger; Alex Soltermann; Saskia Ting; Verena Tischler; Ekkehard Vollmer; Philipp A Schnabel; Wilko Weichert
Journal:  Virchows Arch       Date:  2012-06-23       Impact factor: 4.064

3.  Is spread through alveolar spaces, the newly recognized pattern of invasion, a potential game changer in lung adenocarcinoma?

Authors:  Sarina Bains; Prasad S Adusumilli
Journal:  Ann Transl Med       Date:  2015-12

4.  Significance and evaluation of anaplastic lymphoma kinase by immunohistochemistry in non-small cell lung cancer.

Authors:  Shuting Ding; Nan Liu; Huanyu Zhao; Guiyang Jiang; Xiupeng Zhang; Enhua Wang
Journal:  Tumour Biol       Date:  2016-02-17

Review 5.  The pivotal role of pathology in the management of lung cancer.

Authors:  Morgan R Davidson; Adi F Gazdar; Belinda E Clarke
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

6.  Clinicopathologic correlates of postoperative N1 or N2 nodal upstaging in non-small cell lung cancer.

Authors:  Youngkyu Moon; Kyo Young Lee; Kyung Soo Kim; Jae Kil Park
Journal:  J Thorac Dis       Date:  2016-01       Impact factor: 2.895

7.  Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules.

Authors:  Giuseppe Pelosi; Alessio Pellegrinelli; Alessandra Fabbri; Elena Tamborini; Federica Perrone; Giulio Settanni; Adele Busico; Benedetta Picciani; Maria Adele Testi; Lucia Militti; Patrick Maisonneuve; Barbara Valeri; Angelica Sonzogni; Claudia Proto; Marina Garassino; Filippo De Braud; Ugo Pastorino
Journal:  Virchows Arch       Date:  2016-04-07       Impact factor: 4.064

Review 8.  Unraveling tumor grading and genomic landscape in lung neuroendocrine tumors.

Authors:  Giuseppe Pelosi; Mauro Papotti; Guido Rindi; Aldo Scarpa
Journal:  Endocr Pathol       Date:  2014-06       Impact factor: 3.943

9.  FDG PET-CT SUVmax and IASLC/ATS/ERS histologic classification: a new profile of lung adenocarcinoma with prognostic value.

Authors:  Marina Suárez-Piñera; José Belda-Sanchis; Alvaro Taus; Albert Sánchez-Font; Antoni Mestre-Fusco; Marcel Jiménez; Lara Pijuan
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-04-25

10.  Thyroid transcription factor-1 expression is an independent predictor of recurrence and correlates with the IASLC/ATS/ERS histologic classification in patients with stage I lung adenocarcinoma.

Authors:  Kyuichi Kadota; Jun-Ichi Nitadori; Inderpal S Sarkaria; Camelia S Sima; Xiaoyu Jia; Akihiko Yoshizawa; Valerie W Rusch; William D Travis; Prasad S Adusumilli
Journal:  Cancer       Date:  2012-10-23       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.